A biopharmaceutical company focused on novel immunotherapy agents for cancer and inflammatory diseases.

Investor Relations

Corporate Profile



Investor Tools

  • Email page
  • PDF view
  • Print view
  • Email Alert
  • RSS Feeds
  • Tearsheet
  • Mobile IR Site
  • Social Media Sharing
  • Email page
  • PDF view
  • Print view
  • Email Alert
  • RSS Feeds
  • Tearsheet
  • Mobile IR Site
  • Social Media Sharing

Stock Quote

  • NASDAQCNDO
  • Market Value ($M)122.02
  • Change ($)(0.17)
  • Change (%)(2.53)
  • Volume23,225
  • Stock Quote ($)6.56
As of May 18, 2012 12:37 PM - Minimum 20 minute delay.

Webcast
Coronado Biosciences, Inc. at Future Leaders in the Biotech Industry Conference
Friday, April 20, 2012
3:30 PM ET
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.

Contact Information

Coronado Biosciences, Inc.
15 New England Executive Park
Burlington, MA 01803
Phone: (781) 238-6621
Fax: (781) 459-7788
info@coronadobio.com

Investor Relations
Lucy Lu, MD, EVP & CFO
ir@coronadobio.com
781-238-6619

 

  • Investors
15 New England Executive Park
Burlington, MA 01803
Phone: 781-238-6621
Fax: 781-459-7788
Email: info@coronadobio.com

© Copyright 2012Coronado Biosciences|Privacy Policy|Site Map

 

All releases